Quick Answer
Travere Therapeutics, Inc. reported Total Revenue of $490.73 million for fiscal year 2025.
Travere Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $490.73M +110.5% |
$233.18M +60.5% |
$145.24M +32.7% |
$109.46M -17.0% |
$131.84M -33.5% |
$198.32M +13.1% |
| Revenue (ASC 606) | $490.73M +110.5% |
$233.18M +60.5% |
$145.24M +32.7% |
$109.46M -17.0% |
$131.84M -33.5% |
$198.32M +13.1% |
| Net Income | -$25.55M +92.1% |
-$321.55M -188.6% |
-$111.40M +60.0% |
-$278.48M -54.6% |
-$180.09M -6.3% |
-$169.43M -15.7% |
| Diluted EPS | -$0.29 +92.9% |
-$4.08 -172.0% |
-$1.50 +65.7% |
-$4.37 -45.2% |
-$3.01 +15.4% |
-$3.56 -2.9% |
| Total Assets | $605.19M +1.9% |
$594.12M -24.7% |
$788.91M +17.3% |
$672.59M -13.4% |
$776.63M +27.9% |
$607.44M +0.4% |
| Cash and Equivalents | $93.03M +58.9% |
$58.53M +0.6% |
$58.18M -5.7% |
$61.69M -62.8% |
$165.75M +95.5% |
$84.77M +35.8% |
| Stockholders Equity | $114.83M +94.4% |
$59.08M -70.6% |
$200.81M +368.6% |
$42.85M -85.8% |
$302.11M +43.0% |
$211.21M -4.5% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$62.82M +80.6% |
-$323.83M +16.6% |
-$388.14M -21.4% |
-$319.81M -60.4% |
-$199.43M -13.2% |
-$176.16M -28.2% |
| Shares Outstanding | 90.92M +4.0% |
87.45M +16.0% |
75.37M +17.2% |
64.29M +2.9% |
62.49M +19.6% |
52.25M +21.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $164.86M | +162.1% | +44.0% |
| Revenue (ASC 606) | September 30, 2025 | $164.86M | +162.1% | +44.0% |
| Net Income | September 30, 2025 | $25.71M | +146.9% | +301.5% |
| Diluted EPS | September 30, 2025 | $0.28 | +140.0% | +300.0% |
| Total Assets | September 30, 2025 | $538.58M | +6.8% | -3.0% |
| Cash and Equivalents | September 30, 2025 | $110.93M | +204.7% | +47.6% |
| Stockholders Equity | September 30, 2025 | $73.56M | +341.6% | +124.6% |
| R&D Expense | September 30, 2021 | $48.41M | +49.6% | -6.6% |
| Operating Income | September 30, 2025 | $24.93M | +144.4% | +297.1% |
| Shares Outstanding | September 30, 2025 | 89.46M | +14.8% | +0.4% |
- Travere Therapeutics, Inc. reported Total Revenue of $490.73 million for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +110.5% in Total Revenue compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Revenue (ASC 606) of $490.73 million for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +110.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Net Income of -$25.55 million for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +92.1% in Net Income compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Diluted EPS of $0.29 per share (loss) for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +92.9% in Diluted EPS compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Total Assets of $605.19 million for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +1.9% in Total Assets compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Cash and Equivalents of $93.03 million for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +58.9% in Cash and Equivalents compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Stockholders Equity of $114.83 million for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +94.4% in Stockholders Equity compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported R&D Expense of $140.96 million for fiscal year 2019.
- Travere Therapeutics, Inc. showed an increase of +13.9% in R&D Expense compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Operating Income of -$62.82 million for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +80.6% in Operating Income compared to the prior fiscal year.
- Travere Therapeutics, Inc. reported Shares Outstanding of 90.92 million shares for fiscal year 2025.
- Travere Therapeutics, Inc. showed an increase of +4.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: